Intravitreal injection of bevacizumab for retinopathy of prematurity in an infant with peters anomaly.

Abstract

PURPOSE:

To report our findings in an infant with Peters anomaly type II whose retinopathy of prematurity (ROP) was treated with an anti-VEGF agent and surgeries.

CASE REPORT:

A male infant weighing 548 g was born prematurely at 23 weeks and 1 day with corneal opacity and shallow anterior chambers in both eyes. At the postmenstrual age of 35 weeks and 3 days, the infant was tentatively diagnosed with stage 3 ROP because of a dilated tunica vasculosa lentis and ultrasonographic findings. The boy was treated with bilateral intravitreal injections of bevacizumab (IVB) because laser photocoagulation of the retina could not be performed due to the corneal opacity. The retina in the right eye detached 3 times, namely 5 days, 16 days, and 7 months after the IVB; encircling the scleral buckle and a vitrectomy with endolaser photocoagulation were therefore required. In his left eye, the retina was reattached after the initial IVB, and no additional treatment was required. ROP was not reactivated in both eyes until the last examination at the age of 2 years and 6 months.

CONCLUSIONS:

Our results showed that IVB is a useful treatment for ROP in patients with Peters anomaly. However, a retinal detachment can be a complication after IVB. The optimal timing of IVB for ROP in infants with hazy media needs to be determined.

• Authors: Tsuyoshi Minami, Kazuki Kuniyoshi, Shunji Kusaka, Koji Sugioka, Hiroyuki Sakuramoto, Masuo Sakamoto, Akane Izu, Norihisa Wada, Yoshikazu Shimomura
• Journal: Case reports in ophthalmology (Case Rep Ophthalmol) Vol. 5 Issue 3 Pg. 318-24 (Sep 2014) ISSN: 1663-2699 [Print] Switzerland
• PMID: 25408672 (Publication Type: Case Reports)